aDivision of Paediatric Nephrology, Centre for Paediatric and Adolescent Medicine, University Hospital of Heidelberg, ImNeuenheimer Feld, Germany
bDepartment of Nephrology and Kidney Transplantation, The Children's Memorial Health Institute, AlejaDzieciPolskich
cDepartment of Paediatric Nephrology and Dialysis, Poznan University of Medical Sciences, Poznan
dDepartment of Paediatric and Adolescent Nephrology and Hypertension, Medical University Gdansk, Poland
eDepartment of Pediatrics and Child Health Center, University of Szeged, Hungary
fNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
gNovartisPharma AG, Basel, Switzerland
Correspondence to Professor Franz Schaefer, MD, Division of Pediatric Nephrology, Center for Pediatrics and Adolescent Medicine, University of Heidelberg, Heidelberg, Germany Tel: +49 6221 563 2396; fax: +49 6221 56 5166; e-mail: [email protected]
This article was previously presented as a poster at European Society of Hypertension, June 18–21, Oslo, Norway 2010.
Abbreviations: ABPM, ambulatory blood pressure monitoring; ACEI, angiotensin-converting enzyme inhibitor; AE, adverse event; ANCOVA, analysis of covariance; ARB, angiotensin receptor blocker; ASBP, ambulatory systolic blood pressure; BP, blood pressure; CKD, chronic kidney disease; EMA, European Medicines Agency; GFR, glomerular filtration rate; ITT, intent-to-treat; LOCF, last observation carried forward; LSM, least square means; LVH, left ventricular hypertrophy; MABP, mean ambulatory blood pressure; MSDBP, mean sitting diastolic BP; MSSBP, mean sitting systolic BP; SAE, serious adverse event; SBP, systolic blood pressure; UPCR, urinary protein creatinine ratio
Received 11 April, 2011
Revised 2 August, 2011
Accepted 26 August, 2011
